{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:53:21Z","timestamp":1781578401088,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801756"],"award-info":[{"award-number":["81801756"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171996"],"award-info":[{"award-number":["82171996"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001768"],"award-info":[{"award-number":["82001768"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012238"],"award-info":[{"award-number":["2025A1515012238"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2026A1515011134"],"award-info":[{"award-number":["2026A1515011134"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Projects in Guangzhou","award":["2025A04J4440"],"award-info":[{"award-number":["2025A04J4440"]}]},{"name":"Science and Technology Projects in Guangzhou","award":["2025A03J4117"],"award-info":[{"award-number":["2025A03J4117"]}]},{"name":"Yat-Sen Excellent Young Scientists Fund"},{"name":"National Key R&D Plan of China","award":["2022YFA1104800"],"award-info":[{"award-number":["2022YFA1104800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-05028-y","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:16:02Z","timestamp":1777461362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-armored mesenchymal stem cells potentiate antitumor immunity to combat ovarian cancer"],"prefix":"10.1186","volume":"17","author":[{"given":"Minghui","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingni","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaji","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"10177","key":"5028_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/s0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240\u201353. https:\/\/doi.org\/10.1016\/s0140-6736(18)32552-2.","journal-title":"Lancet"},{"issue":"4","key":"5028_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"5028_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239\u201357. https:\/\/doi.org\/10.1038\/s43018-023-00617-9.","journal-title":"Nat Cancer"},{"issue":"suppl8","key":"5028_CR4","doi-asserted-by":"publisher","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","volume":"28","author":"K Odunsi","year":"2017","unstructured":"Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28(suppl8):viii1\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx444.","journal-title":"Ann Oncol"},{"issue":"2","key":"5028_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/jco.23.01771","volume":"42","author":"J St Laurent","year":"2024","unstructured":"St Laurent J, Liu JF. Treatment Approaches for Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2024;42(2):127\u201333. https:\/\/doi.org\/10.1200\/jco.23.01771.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5028_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"5028_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","volume":"22","author":"LE Kandalaft","year":"2022","unstructured":"Kandalaft LE, Dangaj Laniti D, Coukos G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer. 2022;22(11):640\u201356. https:\/\/doi.org\/10.1038\/s41568-022-00503-z.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"5028_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","volume":"39","author":"J Duraiswamy","year":"2021","unstructured":"Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021;39(12):1623\u2013e4220. https:\/\/doi.org\/10.1016\/j.ccell.2021.10.008.","journal-title":"Cancer Cell"},{"issue":"4","key":"5028_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.immuni.2022.03.006","volume":"55","author":"S D\u00e4hling","year":"2022","unstructured":"D\u00e4hling S, Mansilla AM, Kn\u00f6pper K, Grafen A, Utzschneider DT, Ugur M, et al. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. Immunity. 2022;55(4):656\u2013e708. https:\/\/doi.org\/10.1016\/j.immuni.2022.03.006.","journal-title":"Immunity"},{"issue":"8","key":"5028_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","volume":"6","author":"TA Waldmann","year":"2006","unstructured":"Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595\u2013601. https:\/\/doi.org\/10.1038\/nri1901.","journal-title":"Nat Rev Immunol"},{"issue":"16","key":"5028_CR11","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1158\/1078-0432.Ccr-18-3468","volume":"25","author":"KC Conlon","year":"2019","unstructured":"Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, et al. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion. Clin Cancer Res. 2019;25(16):4945\u201354. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3468.","journal-title":"Clin Cancer Res"},{"key":"5028_CR12","doi-asserted-by":"publisher","first-page":"1184703","DOI":"10.3389\/fphar.2023.1184703","volume":"14","author":"M Cai","year":"2023","unstructured":"Cai M, Huang X, Huang X, Ju D, Zhu YZ, Ye L. Research progress of interleukin-15 in cancer immunotherapy. Front Pharmacol. 2023;14:1184703. https:\/\/doi.org\/10.3389\/fphar.2023.1184703.","journal-title":"Front Pharmacol"},{"issue":"5","key":"5028_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.immuni.2009.08.027","volume":"31","author":"BG Dorner","year":"2009","unstructured":"Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, G\u00fcttler S, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8\u2009+\u2009T cells. Immunity. 2009;31(5):823\u201333. https:\/\/doi.org\/10.1016\/j.immuni.2009.08.027.","journal-title":"Immunity"},{"issue":"6","key":"5028_CR14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12. Immunity. 2018;49(6):1148\u201361. https:\/\/doi.org\/10.1016\/j.immuni.2018.09.024.","journal-title":"Immunity"},{"issue":"5","key":"5028_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017;31(5):711\u2013e234. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.003.","journal-title":"Cancer Cell"},{"issue":"6","key":"5028_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.cell.2015.08.051","volume":"162","author":"S Amigorena","year":"2015","unstructured":"Amigorena S. Helping the Help for CD8\u2009+\u2009T Cell Responses. Cell. 2015;162(6):1210\u20132. https:\/\/doi.org\/10.1016\/j.cell.2015.08.051.","journal-title":"Cell"},{"issue":"1","key":"5028_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","volume":"24","author":"TR Mempel","year":"2024","unstructured":"Mempel TR, Lill JK, Altenburger LM. How chemokines organize the tumour microenvironment. Nat Rev Cancer. 2024;24(1):28\u201350. https:\/\/doi.org\/10.1038\/s41568-023-00635-w.","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"5028_CR18","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1158\/1078-0432.Ccr-18-0945","volume":"24","author":"K Margolin","year":"2018","unstructured":"Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, et al. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2018;24(22):5552\u201361. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0945.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5028_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237\u201353. https:\/\/doi.org\/10.1038\/s41571-021-00588-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8047","key":"5028_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637(8047):940\u20136. https:\/\/doi.org\/10.1038\/s41586-024-08261-8.","journal-title":"Nature"},{"issue":"35","key":"5028_CR21","doi-asserted-by":"publisher","first-page":"eadn9857","DOI":"10.1126\/sciadv.adn9857","volume":"10","author":"P Erler","year":"2024","unstructured":"Erler P, Kurcon T, Cho H, Skinner J, Dixon C, Grudman S, et al. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. Sci Adv. 2024;10(35):eadn9857. https:\/\/doi.org\/10.1126\/sciadv.adn9857.","journal-title":"Sci Adv"},{"issue":"7","key":"5028_CR22","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s41551-021-00815-9","volume":"6","author":"H Wang","year":"2022","unstructured":"Wang H, Alarc\u00f3n CN, Liu B, Watson F, Searles S, Lee CK, et al. Genetically engineered and enucleated human mesenchymal stromal cells for the targeted delivery of therapeutics to diseased tissue. Nat Biomed Eng. 2022;6(7):882\u201397. https:\/\/doi.org\/10.1038\/s41551-021-00815-9.","journal-title":"Nat Biomed Eng"},{"issue":"Pt 6","key":"5028_CR23","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/brain\/awv094","volume":"138","author":"T Bagci-Onder","year":"2015","unstructured":"Bagci-Onder T, Du W, Figueiredo JL, Martinez-Quintanilla J, Shah K. Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain. 2015;138(Pt 6):1710\u201321. https:\/\/doi.org\/10.1093\/brain\/awv094.","journal-title":"Brain"},{"issue":"5","key":"5028_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/ijc.31113","volume":"142","author":"M Cao","year":"2018","unstructured":"Cao M, Mao J, Duan X, Lu L, Zhang F, Lin B, et al. In vivo tracking of the tropism of mesenchymal stem cells to malignant gliomas using reporter gene-based MR imaging. Int J Cancer. 2018;142(5):1033\u201346. https:\/\/doi.org\/10.1002\/ijc.31113.","journal-title":"Int J Cancer"},{"issue":"1","key":"5028_CR25","doi-asserted-by":"publisher","first-page":"e000164","DOI":"10.1136\/jitc-2019-000164","volume":"8","author":"J Mao","year":"2020","unstructured":"Mao J, Cao M, Zhang F, Zhang J, Duan X, Lu L, et al. Peritumoral administration of IFN\u03b2 upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model. J Immunother Cancer. 2020;8(1):e000164. https:\/\/doi.org\/10.1136\/jitc-2019-000164.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"5028_CR26","doi-asserted-by":"publisher","first-page":"e007481","DOI":"10.1136\/jitc-2023-007481","volume":"11","author":"J Mao","year":"2023","unstructured":"Mao J, Li J, Chen J, Wen Q, Cao M, Zhang F, et al. CXCL10 and Nrf2-upregulated mesenchymal stem cells reinvigorate T lymphocytes for combating glioblastoma. J Immunother Cancer. 2023;11(12):e007481. https:\/\/doi.org\/10.1136\/jitc-2023-007481.","journal-title":"J Immunother Cancer"},{"issue":"7769","key":"5028_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1456-0.","journal-title":"Nature"},{"issue":"11","key":"5028_CR28","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.cmet.2023.10.002","volume":"35","author":"J Li","year":"2023","unstructured":"Li J, Zheng C, Mai Q, Huang X, Pan W, Lu J, et al. Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer. Cell Metab. 2023;35(11):2044\u201359. https:\/\/doi.org\/10.1016\/j.cmet.2023.10.002.","journal-title":"Cell Metab"},{"issue":"26","key":"5028_CR29","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollaoglu","year":"2024","unstructured":"Mollaoglu G, Tepper A, Falcomat\u00e0 C, Potak HT, Pia L, Amabile A, et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024;187(26):7492\u2013e51022. https:\/\/doi.org\/10.1016\/j.cell.2024.10.006.","journal-title":"Cell"},{"issue":"5","key":"5028_CR30","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1158\/0008-5472.Can-17-2506","volume":"78","author":"J Kang","year":"2018","unstructured":"Kang J, Shin SH, Yoon H, Huh J, Shin HW, Chun YS, et al. FIH Is an Oxygen Sensor in Ovarian Cancer for G9a\/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes. Cancer Res. 2018;78(5):1184\u201399. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-2506.","journal-title":"Cancer Res"},{"key":"5028_CR31","doi-asserted-by":"publisher","unstructured":"Etzerodt A, Moulin M, Doktor TK, Delfini M, Mossadegh-Keller N, Bajenoff M, et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med. 2020. https:\/\/doi.org\/10.1084\/jem.20191869.","DOI":"10.1084\/jem.20191869"},{"issue":"1","key":"5028_CR32","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1038\/s41467-024-46873-w","volume":"15","author":"L Kasikova","year":"2024","unstructured":"Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat Commun. 2024;15(1):2528. https:\/\/doi.org\/10.1038\/s41467-024-46873-w.","journal-title":"Nat Commun"},{"issue":"3","key":"5028_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/neuonc\/nor204","volume":"14","author":"E Binello","year":"2012","unstructured":"Binello E, Germano IM. Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol. 2012;14(3):256\u201365. https:\/\/doi.org\/10.1093\/neuonc\/nor204.","journal-title":"Neuro Oncol"},{"issue":"4","key":"5028_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/cgt.2009.67","volume":"17","author":"JL Dembinski","year":"2010","unstructured":"Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, et al. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther. 2010;17(4):289\u201397. https:\/\/doi.org\/10.1038\/cgt.2009.67.","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"5028_CR35","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nbt.2993","volume":"32","author":"AV Naumova","year":"2014","unstructured":"Naumova AV, Modo M, Moore A, Murry CE, Frank JA. Clinical imaging in regenerative medicine. Nat Biotechnol. 2014;32(8):804\u201318. https:\/\/doi.org\/10.1038\/nbt.2993.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"5028_CR36","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/stem.645","volume":"29","author":"MR Reagan","year":"2011","unstructured":"Reagan MR, Kaplan DL. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells. 2011;29(6):920\u20137. https:\/\/doi.org\/10.1002\/stem.645.","journal-title":"Stem Cells"},{"issue":"10","key":"5028_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/gt.2008.39","volume":"15","author":"E Spaeth","year":"2008","unstructured":"Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008;15(10):730\u20138. https:\/\/doi.org\/10.1038\/gt.2008.39.","journal-title":"Gene Ther"},{"issue":"5","key":"5028_CR38","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1634\/stemcells.2005-0271","volume":"24","author":"BR Son","year":"2006","unstructured":"Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells. 2006;24(5):1254\u201364. https:\/\/doi.org\/10.1634\/stemcells.2005-0271.","journal-title":"Stem Cells"},{"issue":"3","key":"5028_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151\u201367. https:\/\/doi.org\/10.1038\/s41571-018-0142-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"5028_CR40","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.Can-14-3098","volume":"75","author":"J Peng","year":"2015","unstructured":"Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, et al. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-\u03baB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Res. 2015;75(23):5034\u201345. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-3098.","journal-title":"Cancer Res"},{"issue":"3","key":"5028_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41423-019-0305-2","volume":"17","author":"D Cai","year":"2020","unstructured":"Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, et al. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol. 2020;17(3):227\u201336. https:\/\/doi.org\/10.1038\/s41423-019-0305-2.","journal-title":"Cell Mol Immunol"},{"key":"5028_CR42","doi-asserted-by":"publisher","unstructured":"Conejo-Garcia JR, Rutkowski MR, Cubillos-Ruiz JR. State-of-the-art of regulatory dendritic cells in cancer. Pharmacol Ther. 2016. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.04.003","DOI":"10.1016\/j.pharmthera.2016.04.003"},{"issue":"5","key":"5028_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298\u2013312. https:\/\/doi.org\/10.1038\/s41568-021-00339-z.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"5028_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"5028_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"5028_CR46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo I, Ad\u00e1n-Barrientos I, Gal\u00e1n M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21(4):257\u201377. https:\/\/doi.org\/10.1038\/s41571-024-00859-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"5028_CR47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/sj.gt.3303105","volume":"15","author":"JA Curtin","year":"2008","unstructured":"Curtin JA, Dane AP, Swanson A, Alexander IE, Ginn SL. Bidirectional promoter interference between two widely used internal heterologous promoters in a late-generation lentiviral construct. Gene Ther. 2008;15(5):384\u201390. https:\/\/doi.org\/10.1038\/sj.gt.3303105.","journal-title":"Gene Ther"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05028-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05028-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05028-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:47:40Z","timestamp":1781578060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05028-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5028"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05028-y","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with the ARRIVE guidelines. This study received ethical approval from the Institutional Animal Care and Use Committee (IACUC) of Sun Yat-Sen University (Approval No. SYSU-IACUC-2021-B1448; Title: Multimodality Molecular Imaging Study of Immunotherapy for Advanced Ovarian Cancer with Targeted Delivery of IL-15 and XCL1 by Mesenchymal Stem Cells) on July 23, 2021. Additional approval for specific procedures was obtained from the IACUC of Bojin Biotechnology (Guangzhou, China) (Approval No. BG-AMS-231201-CH01-Y; Title: Molecular Imaging of Mesenchymal Stem Cells Targeting the Malignant Tumor Immune Microenvironment) on December 9, 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}